Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue

[1]  E. Coulson,et al.  The p75 neurotrophin receptor. , 2008, The international journal of biochemistry & cell biology.

[2]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[3]  F. Schmitt,et al.  p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas , 2005, Virchows Archiv.

[4]  H. Enzan,et al.  Consistent lack of CD34-positive stromal cells in the stroma of malignant breast lesions. , 2005, Histology and histopathology.

[5]  H. Denk,et al.  Metaplastic Breast Carcinomas: Are They of Myoepithelial Differentiation?: Immunohistochemical Profile of the Sarcomatoid Subtype Using Novel Myoepithelial Markers , 2005, The American journal of surgical pathology.

[6]  L. True,et al.  Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. , 2004, The American journal of pathology.

[7]  Jorge S. Reis-Filho,et al.  Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes , 2004, Clinical Cancer Research.

[8]  Fatima S. Khwaja,et al.  Ibuprofen Inhibits Survival of Bladder Cancer Cells by Induced Expression of the p75NTR Tumor Suppressor Protein , 2004, Cancer Research.

[9]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[10]  Melinda F Lerwill,et al.  Current Practical Applications of Diagnostic Immunohistochemistry in Breast Pathology , 2004, The American journal of surgical pathology.

[11]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[12]  Alan Mackay,et al.  Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. , 2004, Cancer research.

[13]  S. Lakhani,et al.  Distribution and significance of 14‐3‐3σ, a novel myoepithelial marker, in normal, benign, and malignant breast tissue , 2004, The Journal of pathology.

[14]  I. Ellis,et al.  An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. , 2003, Human pathology.

[15]  Z. Gatalica,et al.  Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas. , 2003, American journal of clinical pathology.

[16]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Bredesen,et al.  Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR). , 2003, Cytokine & growth factor reviews.

[18]  Fatima S. Khwaja,et al.  The p75NTR tumor suppressor induces caspase‐mediated apoptosis in bladder tumor cells , 2003, International journal of cancer.

[19]  H. Hondermarck,et al.  Tumor Necrosis Factor Receptor-associated Death Domain Protein Is Involved in the Neurotrophin Receptor-mediated Antiapoptotic Activity of Nerve Growth Factor in Breast Cancer Cells* , 2003, The Journal of Biological Chemistry.

[20]  J. Pringle,et al.  There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions , 2003, Journal of clinical pathology.

[21]  Fatima S. Khwaja,et al.  Inhibition of cell‐cycle effectors of proliferation in bladder tumor epithelial cells by the p75NTR tumor suppressor , 2003, Molecular carcinogenesis.

[22]  J. Reis-Filho,et al.  Novel and Classic Myoepithelial/Stem Cell Markers in Metaplastic Carcinomas of the Breast , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[23]  F. Schmitt,et al.  p63 expression in sarcomatoid/metaplastic carcinomas of the breast , 2003, Histopathology.

[24]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .

[25]  J. Reis-Filho,et al.  Taking Advantage of Basic Research: p63 Is a Reliable Myoepithelial and Stem Cell Marker , 2002, Advances in anatomic pathology.

[26]  D. Djakiew,et al.  Neurotrophin receptor p75NTR suppresses growth and nerve growth factor‐mediated metastasis of human prostate cancer cells , 2002 .

[27]  R. Moll,et al.  CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions , 2002, Virchows Archiv.

[28]  M Dietel,et al.  Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. , 2001, American journal of clinical pathology.

[29]  D. Djakiew,et al.  The neurotrophin receptor p75NTR is a tumor suppressor in human prostate cancer. , 2001, Anticancer research.

[30]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Y. Sakamoto,et al.  Combined evaluation of NGF and p75NGFR expression is a biomarker for predicting prognosis in human invasive ductal breast carcinoma. , 2001, Oncology reports.

[32]  F. Révillion,et al.  Expression of nerve growth factor receptors and their prognostic value in human breast cancer. , 2001, Cancer research.

[33]  J. Peyrat,et al.  Nerve Growth Factor Stimulates Proliferation and Survival of Human Breast Cancer Cells through Two Distinct Signaling Pathways* , 2001, The Journal of Biological Chemistry.

[34]  D. Djakiew,et al.  Molecular characterization of the loss of p75NTR expression in human prostate tumor cells , 2001, Molecular carcinogenesis.

[35]  A. Lee,et al.  Expression of CD34 and bcl‐2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast , 2001, Histopathology.

[36]  J. Reis-Filho,et al.  Maspin expression in myoepithelial tumors of the breast. , 2001, Pathology, research and practice.

[37]  H. Harn,et al.  CD34, CD117, and actin expression in phyllodes tumor of the breast. , 2000, The Journal of surgical research.

[38]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[39]  A. Huvos,et al.  Myoepithelial carcinoma of the salivary glands: a clinicopathologic study of 25 patients. , 2000, The American journal of surgical pathology.

[40]  A. Gown,et al.  Detection of Stromal Invasion in Breast Cancer: The Myoepithelial Markers , 2000, Advances in anatomic pathology.

[41]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[42]  T. Chao,et al.  Metaplastic carcinomas of the breast , 1999, Journal of surgical oncology.

[43]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  B. Chapman.  A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR‐I and Fas , 1995, FEBS letters.

[45]  D. Djakiew,et al.  Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. , 1992, Cancer research.

[46]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[47]  P. Sloan,et al.  Spindle-cell carcinoma: a case report. , 1990, The British journal of oral & maxillofacial surgery.

[48]  H. Norris,et al.  Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin , 1990, Cancer.

[49]  H. Norris,et al.  Metaplastic carcinomas of the breast. III. Carcinosarcoma , 1989, Cancer.

[50]  A. Gown,et al.  A monoclonal antibody against nerve growth factor receptor. Immunohistochemical analysis of normal and neoplastic human tissue. , 1989, American journal of clinical pathology.

[51]  H. Norris,et al.  Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. , 1989, Human pathology.

[52]  H. Norris,et al.  Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. , 1989, Human pathology.

[53]  J. Hoxie,et al.  The nerve growth factor receptor gene is at human chromosome region 17q12-17q22, distal to the chromosome 17 breakpoint in acute leukemias. , 1986, Proceedings of the National Academy of Sciences of the United States of America.